BillionToOne is trading 7.1% down at $105.83 on November 5 after its earnings call, with investors potentially weighing details despite third-quarter revenue and earnings above estimates and a raised 2026 revenue outlook. - One report described shares indicating a 12% decline after the call. Possible concerns include a one-time revenue true-up, slowing growth and uncertainty around Medicare coverage. - The biotech sector gained 2.05%, moving in the opposite direction and not explaining the decline.